Spoken Alpha
Adagio Medical Holdings, Inc.
Adagio Medical designs and develops catheter-based cryoablation systems for treating cardiac arrhythmias, specifically ventricular tachycardia in patients with structural heart disease. The company's proprietary Ultra-Low Temperature Ablation (ULTA) technology creates deep, durable lesions in heart tissue to eliminate abnormal electrical pathways.
Adagio Medical Holdings, Inc is a Healthcare company operating in Medical Devices with a $14.3M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 11, 2026).
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add ADGM, reply to your welcome email and we'll prioritize it.
History
Spoken Alpha tracks ADGM's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 8/10 quarters but stock falls 60% of the time
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ADGM.
$ curl https://api.spokenalpha.com/v1/companies/ADGMFAQ
Spoken Alpha indexes ADGM's earnings call transcripts at https://spokenalpha.com/companies/ADGM. Each call links to attributed speakers and parsed analyst Q&A. Adagio Medical Holdings, Inc.'s own investor relations page is at https://investors.adagiomedical.com/.
Adagio Medical Holdings, Inc. (ADGM) operates in the Healthcare sector (Medical Devices industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-11 | — | $-0.38 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-05-11 | $-0.31 | $-0.29 | -6.9% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-26 | $-0.16 | $-0.31 | +48.4% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-11 | $-0.66 | $0.00 | — | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-13 | $-0.35 | — | — | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-14 | $-0.51 | — | — | $-143.0K | — | — | EODHD |
| Q4 FY2024 | 2025-03-26 | $-3.75 | — | — | — | — | — | EODHD |
| Q3 FY2024 | 2024-09-29 | $-0.32 | — | — | $185.0K | — | — | EODHD |
| Q2 FY2024 | 2024-06-29 | $-713794.00 | — | — | $254.0K | — | — | EODHD |
| Q1 FY2024 | 2024-03-30 | $-0.03 | — | — | $26.0K | — | — | EODHD |
| Q4 FY2023 | 2023-12-30 | $-0.28 | — | — | $78.0K | — | — | EODHD |
| Q3 FY2023 | 2023-09-29 | $-0.06 | — | — | $41.0K | — | — | EODHD |
| Q2 FY2023 | 2023-06-29 | $0.05 | — | — | $121.0K | — | — | EODHD |
| Q1 FY2023 | 2023-04-05 | $0.05 | — | — | $60.0K | — | — | EODHD |
| Q4 FY2022 | 2022-12-30 | $-0.09 | — | — | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-06 | $0.17 | — | — | — | — | — | EODHD |
| Q2 FY2022 | 2022-08-07 | $-0.01 | — | — | — | — | — | EODHD |
| Q1 FY2022 | 2022-05-12 | $-0.01 | — | — | — | — | — | EODHD |
| Q4 FY2021 | 2022-03-30 | $-0.06 | — | — | — | — | — | EODHD |
| Q3 FY2021 | 2021-11-11 | $-0.27 | — | — | — | — | — | EODHD |
Source: EODHD. ADGM reported actuals as published; sparse fields render as —.
When a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $3.32 | $3.13 | +6.2% | -1.9% | -4.0% |
| Q4 FY2026 | $3.10 | $3.08 | +0.7% | +4.8% | +6.3% |
| Q3 FY2026 | $3.13 | $3.12 | +0.3% | +2.5% | +3.8% |
| Q2 FY2026 | $3.09 | $3.01 | +2.6% | +1.2% | +1.2% |
| Q1 FY2025 | $3.48 | $3.23 | +7.8% | -1.6% | -4.3% |
CFO since 2025 • 2/4 beats (50%) • last guidance cut Q2 FY2026
| Q4 FY2025 |
| $3.23 |
| $3.07 |
| +5.2% |
| -2.7% |
| -1.5% |
| Q3 FY2025 | $3.28 | $3.23 | +1.7% | -1.6% | -4.4% |
| Q2 FY2025 | $3.08 | $3.13 | -1.7% | +8.0% | +9.5% |
| Q1 FY2024 | $3.30 | $3.35 | -1.6% | -2.7% | -1.5% |
| Q4 FY2024 | $3.35 | $3.33 | +0.6% | -0.1% | -1.7% |